OGN Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Organon & (NYSE: OGN)
›
Organon & (NYSE: OGN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 10,000 employees.
The shares were at 13.91 USD on 19 November 2026, up 86.0% over 52 weeks. Its 52-week range is 5.690 USD to 13.94 USD, and it trades at the top of that range.
At a market capitalisation of 3.65B USD, it trades at 17.8 times trailing earnings and 3.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 32% for OGN. It pays a dividend yielding 0.57% (it pays out 10% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Organon & reports return on equity of 24.9%, an operating margin of 19.8% and revenue down 1.7% year over year.
Its debt exceeds its cash by 7.10B USD, a debt-to-equity ratio of 11.49. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 10.33 USD is 25.7% below the current price. The next earnings report is expected on 11 February 2027.